NAPA, Calif.-- Senetek PLC (OTCBB: SNKTY), a life sciences company engaged in the development of technologies that target the science of healthy aging, launched Pyratine-6™, a new cytokinin technology that works faster than kinetin or any other product on the market in dramatically reducing roughness and redness starting in as little as two weeks, with full results on fine wrinkles, dryness, discoloration, and other signs of photodamage in twelve weeks of consistent use. Clinical studies have shown improvement in pre-existing redness associated with rosacea, eczema, contact dermatitis and menopause.
Cytokinins are natural plant-derived growth factors that stimulate growth and differentiation. While they do not stimulate proliferation of human cells, cytokinins have proved to be superior anti-aging agents in skin cells. By functioning as antioxidants, they purge cellular debris and delay the aging process.
In a clinical study of 34 patients, Pyratine-6 was well tolerated by 33 of the patients. Because it is non-acidic and without irritants, Pyratine-6 showed zero on a 4-point scale of irritation and can be used in conjunction with treatment procedures such as chemical peels, laser resurfacing, microdermabrasion and injectables. It has no know interactions with drugs or other products and, it can be used before the application of cosmetics and in conjunction with sunscreen and other enhancement products.
In an independent study from the University of California, Irvine published in the February 2008 Journal of Drugs in Dermatology, Dr. Jerry L. McCullough stated: "Treatment with Pyratine-6™ (0.1%) over 12 weeks improves roughness and skin moisturization in two weeks and hyperpigmentation and fine wrinkles in four weeks." Further, the report stated that adverse effects of Pyratine-6™ are "minimal" and "transient."